Does the media refer more to ZBH or BLCO?

In the previous week, Zimmer Biomet had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 11 mentions for Zimmer Biomet and 7 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.16 beat Bausch + Lomb's score of 0.56 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is SOLV or BLCO more profitable?

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Bausch + Lomb -4.21% 3.60% 1.69%

Does the media prefer SOLV or BLCO?

In the previous week, Solventum had 2 more articles in the media than Bausch + Lomb. MarketBeat recorded 9 mentions for Solventum and 7 mentions for Bausch + Lomb. Solventum's average media sentiment score of 1.32 beat Bausch + Lomb's score of 0.56 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SNN or BLCO?

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.13 $625M N/A N/A Bausch + Lomb $5.10B 1.14 -$360M -$0.62 N/A

Does the media prefer SNN or BLCO?

In the previous week, Bausch + Lomb had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 7 mentions for Bausch + Lomb and 4 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.76 beat Bausch + Lomb's score of 0.56 indicating that Smith & Nephew SNATS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is PEN or BLCO more profitable?

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 11.76% 10.87% 8.45% Bausch + Lomb -4.21% 3.60% 1.69%

Does the media prefer PEN or BLCO?

In the previous week, Bausch + Lomb had 4 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Bausch + Lomb and 3 mentions for Penumbra. Bausch + Lomb's average media sentiment score of 0.56 beat Penumbra's score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, BLCO or GKOS?

Glaukos has lower revenue, but higher earnings than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch + Lomb $5.10B 1.14 -$360M -$0.62 N/A Glaukos $551.35M 16.27 -$187.69M -$3.28 N/A

Is BLCO or GKOS more profitable?

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -4.21% 3.60% 1.69% Glaukos -34.34% -6.92% -5.25%

Does the media favor BLCO or GKOS?

In the previous week, Glaukos had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 10 mentions for Glaukos and 7 mentions for Bausch + Lomb. Glaukos' average media sentiment score of 0.65 beat Bausch + Lomb's score of 0.56 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bausch + Lomb (BLCO) Competitors

$16.25 +0.02 (+0.12%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$16.00 -0.25 (-1.54%)

As of 07/13/2026 07:57 PM Eastern

Compare

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy Bausch + Lomb stock or one of its competitors? MarketBeat compares Bausch + Lomb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch + Lomb include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does Bausch + Lomb compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Zimmer Biomet has a net margin of 9.05% compared to Bausch + Lomb's net margin of -4.21%. Zimmer Biomet's return on equity of 13.24% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Bausch + Lomb	-4.21%	3.60%	1.69%

Zimmer Biomet currently has a consensus target price of $102.33, suggesting a potential upside of 8.76%. Bausch + Lomb has a consensus target price of $18.00, suggesting a potential upside of 10.77%. Given Bausch + Lomb's higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.25
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Zimmer Biomet had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 11 mentions for Zimmer Biomet and 7 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.16 beat Bausch + Lomb's score of 0.56 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.21	$705.20M	$3.85	24.44
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A

Summary

Zimmer Biomet beats Bausch + Lomb on 14 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Solventum?

Solventum (NYSE:SOLV) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

11.1% of Bausch + Lomb shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Solventum had 2 more articles in the media than Bausch + Lomb. MarketBeat recorded 9 mentions for Solventum and 7 mentions for Bausch + Lomb. Solventum's average media sentiment score of 1.32 beat Bausch + Lomb's score of 0.56 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum presently has a consensus price target of $83.67, suggesting a potential upside of 7.98%. Bausch + Lomb has a consensus price target of $18.00, suggesting a potential upside of 10.77%. Given Bausch + Lomb's higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.61	$1.56B	$8.16	9.50
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A

Solventum has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Bausch + Lomb	-4.21%	3.60%	1.69%

Summary

Solventum beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Smith & Nephew SNATS currently has a consensus price target of $30.93, indicating a potential downside of 0.49%. Bausch + Lomb has a consensus price target of $18.00, indicating a potential upside of 10.77%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Smith & Nephew SNATS has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Bausch + Lomb	-4.21%	3.60%	1.69%

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.13	$625M	N/A	N/A
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A

In the previous week, Bausch + Lomb had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 7 mentions for Bausch + Lomb and 4 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.76 beat Bausch + Lomb's score of 0.56 indicating that Smith & Nephew SNATS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bausch + Lomb beats Smith & Nephew SNATS on 7 of the 13 factors compared between the two stocks.

How does Bausch + Lomb compare to Penumbra?

Penumbra (NYSE:PEN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Penumbra has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Penumbra currently has a consensus price target of $360.33, indicating a potential upside of 13.09%. Bausch + Lomb has a consensus price target of $18.00, indicating a potential upside of 10.77%. Given Penumbra's higher probable upside, equities analysts plainly believe Penumbra is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, Bausch + Lomb had 4 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Bausch + Lomb and 3 mentions for Penumbra. Bausch + Lomb's average media sentiment score of 0.56 beat Penumbra's score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.45B	8.62	$177.69M	$4.34	73.41
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.9% of Penumbra shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Bausch + Lomb	-4.21%	3.60%	1.69%

Summary

Penumbra beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Glaukos?

Bausch + Lomb (NYSE:BLCO) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Bausch + Lomb currently has a consensus price target of $18.00, indicating a potential upside of 10.77%. Glaukos has a consensus price target of $151.77, indicating a potential downside of 0.65%. Given Bausch + Lomb's higher possible upside, equities research analysts clearly believe Bausch + Lomb is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Glaukos has lower revenue, but higher earnings than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A
Glaukos	$551.35M	16.27	-$187.69M	-$3.28	N/A

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Glaukos	-34.34%	-6.92%	-5.25%

In the previous week, Glaukos had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 10 mentions for Glaukos and 7 mentions for Bausch + Lomb. Glaukos' average media sentiment score of 0.65 beat Bausch + Lomb's score of 0.56 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Glaukos beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$5.80B	$9.60B	$7.05B	$23.46B
Dividend Yield	N/A	1.62%	2.68%	4.02%
P/E Ratio	-26.21	26.00	27.11	31.08
Price / Sales	1.14	17.40	587.92	19.77
Price / Cash	9.73	14.81	29.22	18.64
Price / Book	0.88	6.05	10.75	4.77
Net Income	-$360M	$177.20M	$3.58B	$1.06B
7 Day Performance	-5.22%	-2.07%	-2.06%	-0.23%
1 Month Performance	7.72%	6.96%	3.32%	-0.11%
1 Year Performance	18.92%	11.42%	26.35%	16.46%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	3.6998 of 5 stars	$16.25 +0.1%	$18.00 +10.8%	+17.1%	$5.80B	$5.10B	N/A	13,000
ZBH Zimmer Biomet	3.5278 of 5 stars	$87.50 +0.0%	$102.70 +17.4%	+0.2%	$16.92B	$8.41B	22.73	17,000	Positive News
SOLV Solventum	3.9393 of 5 stars	$78.22 -0.1%	$83.73 +7.0%	+5.1%	$13.55B	$8.26B	9.59	20,000	Positive News Analyst Forecast
SNN Smith & Nephew SNATS	2.0246 of 5 stars	$30.26 +0.0%	$30.93 +2.2%	+2.6%	$12.86B	$6.16B	N/A	16,988	News Coverage
PEN Penumbra	1.6173 of 5 stars	$318.54 0.0%	$361.33 +13.4%	+34.2%	$12.53B	$1.40B	73.40	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Summary

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Summary

How does Bausch + Lomb compare to Penumbra?

Summary

How does Bausch + Lomb compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Is ZBH or BLCO more profitable?

Do analysts recommend ZBH or BLCO?

Do institutionals & insiders hold more shares of ZBH or BLCO?

Does the media refer more to ZBH or BLCO?

Which has more risk and volatility, ZBH or BLCO?

Which has stronger valuation and earnings, ZBH or BLCO?

Summary

How does Bausch + Lomb compare to Solventum?

Do institutionals and insiders hold more shares of SOLV or BLCO?

Does the media prefer SOLV or BLCO?

Do analysts recommend SOLV or BLCO?

Which has better earnings & valuation, SOLV or BLCO?

Which has more volatility and risk, SOLV or BLCO?

Is SOLV or BLCO more profitable?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Do institutionals & insiders have more ownership in SNN or BLCO?

Do analysts recommend SNN or BLCO?

Which has more volatility & risk, SNN or BLCO?

Is SNN or BLCO more profitable?

Which has higher earnings & valuation, SNN or BLCO?

Does the media prefer SNN or BLCO?

Summary

How does Bausch + Lomb compare to Penumbra?

Which has more risk & volatility, PEN or BLCO?

Do analysts recommend PEN or BLCO?

Does the media prefer PEN or BLCO?

Which has better earnings and valuation, PEN or BLCO?

Do insiders and institutionals have more ownership in PEN or BLCO?

Is PEN or BLCO more profitable?

Summary

How does Bausch + Lomb compare to Glaukos?

Which has more volatility and risk, BLCO or GKOS?

Do analysts prefer BLCO or GKOS?

Do institutionals and insiders have more ownership in BLCO or GKOS?

Which has preferable earnings & valuation, BLCO or GKOS?

Is BLCO or GKOS more profitable?

Does the media favor BLCO or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools